Quick answer
What do "Selank nasal spray formulation" studies involve in a research setting? Published rodent work compares intranasal with intraperitoneal administration of Selank, and reports hippocampal gene-expression and BDNF readouts after intranasal exposure. Those papers describe a route used in animals, not a finished product. The formulation questions that matter in the laboratory are tonicity, pH, preservative, viscosity, adsorption to device surfaces and how long a prepared solution stays intact. V8 Peptides supplies Selank only as a 10 mg lyophilized vial (≥98% HPLC), so any solution is prepared by the researcher from the powder. For laboratory research use only.
People searching for Selank nasal spray formulations are usually asking two different questions at once: what did published animal studies do when they gave Selank by the intranasal route, and what must a laboratory think about when it prepares a peptide solution for that kind of experiment? This article keeps the two apart. The first is a literature summary. The second is formulation reasoning from general peptide science, labeled as such. Nothing here recommends a quantity or describes use outside a research protocol; the material is for laboratory research use only. For the compound's background see the Selank research guide.
What is supplied and what is not
The Selank product page lists a lyophilized powder in a sealed clear glass vial, 10 mg, purity stated as ≥98% by HPLC, molecular formula C33H57N11O9, stored at 2–8 °C with −20 °C for long-term holding and protected from heat, moisture and light. It is a research vial, not a metered device and not a ready-made solution. Every nasal-route experiment therefore starts with dissolving a powder, and the quality of that solution is under the researcher's control.
| Item | Supplied | Researcher decides |
|---|---|---|
| Peptide | 10 mg lyophilized Selank, ≥98% HPLC | Stock concentration and aliquot size |
| Diluent | Not included with the vial | Sterile water, bacteriostatic water or a buffered saline |
| Delivery device | None | Micropipette, atomizer or other apparatus suited to the species |
| Documentation | Lot number, COA where published | Which records to file with each experiment |
Lot data are reported on the COA page where they have been published; how to read a COA explains the fields.
What intranasal Selank studies in animals reported
Several rodent studies used the intranasal route. A study of BALB/c and C57BL/6 mice administered Selank at 300 µg/kg/day for 5 days either intranasally or intraperitoneally and measured elevated plus-maze behavior and brain receptor-binding markers; the anxiolytic- and nootropic-like effects were observed by both routes, but only in BALB/c mice, the strain with lower baseline exploration and higher anxiety (reference 1). A hippocampal microarray study in rats reported that mRNA levels of 36 genes changed more than two-fold after a single intranasal administration of Selank at 200 µg/kg, and 20 genes after a course; most of the affected genes encoded plasma-membrane proteins, which the authors read as pointing toward ion homeostasis in hippocampal cells (reference 2). A third report is titled as showing that intranasal administration of Selank regulates BDNF expression in the rat hippocampus in vivo (reference 3). Only its title was available for this article's source check, so the details are not described here.
Two things follow for design. The route was chosen in these papers to allow comparison with systemic administration and to access brain tissue without surgery, and the behavioral outcome was seen with both routes in the mouse comparison, although the receptor-binding markers differed by route (about 38% more GABA-receptor binding sites in frontal cortex after intraperitoneal administration versus about 23% more MK-801 binding sites in hippocampus after intranasal administration), which the authors attributed to possible differences in pharmacokinetics and biotransformation. A laboratory cannot assume that a peptide reaches a particular brain region in measurable amounts just because it was given intranasally; that has to be measured, for example by tissue extraction and LC-MS, or inferred from a downstream readout with proper controls. The wider literature on the nasal route describes the mucosa as having a large surface area, no first-pass metabolism and potential for central nervous system delivery, while noting that peptides often need permeation enhancers (reference 4). Those are general statements about the route, not findings about Selank.
Formulation variables a laboratory has to control
The variables below come from general peptide and nasal-delivery reasoning (reference 4 and the stability reviews in references 5 and 6). They are not specific findings about Selank.
| Variable | Why it matters for a peptide solution | What to record |
|---|---|---|
| Tonicity | Nasal tissue is sensitive to strongly hypo- or hypertonic fluids; a water-only solution is hypotonic | Diluent, osmolality if measured |
| pH | Affects peptide charge, solubility and chemical stability, and tolerance of the mucosa | Buffer, final pH |
| Preservative | Benzyl alcohol in bacteriostatic water limits microbial growth in a multi-entry vial but is a variable in a nasal or behavioral vehicle | Diluent type and lot |
| Viscosity and volume | Rodent nostrils hold only microliter volumes; viscosity changes how a drop spreads | Volume per administration, vehicle composition |
| Surface adsorption | Dilute peptide solutions lose material to plastic, tips and atomizer parts | Container material, hold time |
| Permeation enhancers | Change both uptake and mucosal tolerance, so they alter the experiment | Name and concentration, with matching vehicle control |
Selank has no tryptophan, methionine or cysteine, so oxidation and disulfide chemistry are not its dominant risks. Deamidation requires asparagine or glutamine and the sequence has neither (Thr-Lys-Pro-Arg-Pro-Gly-Pro), though the proline-rich backbone is still exposed to peptidases, including those in nasal secretions. That is one reason a fresh solution is better than an old one, and why the matching vehicle control should be drawn from the same preparation. General degradation pathways, including deamidation and isomerization, are reviewed in references 5 and 7.
Preparing a stock solution from the vial
The arithmetic is simple and should be done on paper before the vial is opened: C (mg/mL) = m (mg) ÷ V (mL). If a protocol needs a working solution of a specified strength, the required stock volume is V_stock = (C_working × V_final) ÷ C_stock. Use the reconstitution calculator to avoid slips, and put the figures in the notebook. For a nasal-route experiment, a second step is usually necessary: a high-concentration stock in a stable diluent, then a fresh dilution into the final vehicle shortly before administration, so that the dilute form spends as little time as possible in contact with plastic.
- Allow the sealed vial to reach room temperature before opening, so moisture does not condense onto the powder.
- Add the diluent slowly along the glass wall and let the cake dissolve; swirl, do not shake.
- Inspect the solution: it should be clear and colorless. Haze or particles are reasons to stop and record the observation.
- Label with lot, concentration, date and diluent.
- Divide into single-use portions if freezing, and thaw once.
These steps are the same as for any lyophilized peptide; see how to reconstitute a lyophilized peptide, how long reconstituted peptides last and Selank purity testing. Freezing stresses, including concentration of solutes and ice interfaces, are discussed in the freeze-stability literature (reference 8).
Route comparison as an experimental design problem
The mouse comparison summarized earlier shows how to frame the question properly. Intranasal and intraperitoneal groups should share peptide lot, concentration, schedule and animal strain, so that route is the only variable. Each route needs its own vehicle control, because the nasal vehicle (volume, tonicity, enhancers) differs from the systemic one. A third naive group quantifies baseline behavior. Readouts should include at least one behavioral measure and one molecular one, and the molecular one should be collected at a time chosen from the published expression data rather than at convenience. The Selank frontal-cortex gene-expression work, for example, found changes in many genes at 1 hour and fewer at 3 hours after administration (reference 9), a reminder that timing can change the result as much as route does.
Distribution is a separate question from effect. A paper titled as a comparative analysis of how glyprolines are distributed after administration by various routes exists in the literature (reference 10); it was not available in abstract for this article, so it is cited only for its subject. Where distribution matters to the conclusion, a tissue measurement is more persuasive than an inference from behavior.
Quality, storage and record-keeping
Because a nasal-route experiment uses small volumes of dilute solution, small errors in preparation translate directly into variable exposure. Three controls help. First, verify the mass and concentration arithmetic twice. Second, keep the lyophilized vials refrigerated or frozen as the product page states, and do not store the diluted working solution beyond the experiment. Third, file the lot record: the HPLC purity explainer shows why a ≥98% figure describes chromatographic purity and not peptide content, which is a distinction that matters when a protocol is specified by mass.
For sourcing questions, see where to buy Selank; for the wider set of research peptides, browse the shop. The related comparison with its sister heptapeptide is in Selank versus Semax.
Limits of what the literature supports
The intranasal Selank papers are preclinical, are concentrated in a small number of laboratories, and in several cases are published in regional journals whose full text is hard to obtain. Reported amounts are given per kilogram of animal weight and describe what each study used. They do not translate into any claim about other species or settings, and this article makes none. The reasonable summary is narrow: intranasal administration has been used in rodent work on Selank, effects on hippocampal expression and BDNF were reported, and the formulation of a laboratory solution is a set of controllable variables that the researcher owns and must document. All material discussed is for laboratory research use only.
Frequently asked questions
Does V8 Peptides sell Selank as a nasal spray?
No. The product page lists Selank as a 10 mg lyophilized powder in a sealed glass vial, for laboratory research use only. Any solution is prepared by the researcher.
What did intranasal Selank studies in rodents measure?
Published abstracts describe elevated plus-maze behavior and receptor-binding markers in mice, and hippocampal gene-expression and BDNF readouts in rats, with comparisons to intraperitoneal administration in one mouse study.
Did the route change the result in mice?
In the cited BALB/c and C57BL/6 comparison, effects were seen with both intranasal and intraperitoneal administration, but only in BALB/c mice. Strain separated the behavioral outcomes, but the receptor-binding markers differed by route, so route is not irrelevant.
What diluent suits a peptide solution for nasal-route experiments?
That is a protocol decision. Sterile water is hypotonic, bacteriostatic water contains benzyl alcohol, and a buffered saline controls tonicity and pH. Whatever is chosen must be matched in the vehicle control and recorded.
Is Selank prone to oxidation in solution?
Its sequence has no tryptophan, methionine or cysteine, so oxidation and disulfide chemistry are not the main concerns. Peptidases, adsorption and microbial growth are more relevant.
Why does adsorption matter for small volumes?
Dilute peptide solutions lose a larger fraction of material to plastic surfaces. Low-binding tubes, few transfers and fresh dilution shortly before use limit the loss.
How is stock concentration calculated?
Concentration in mg/mL equals vial mass in mg divided by diluent volume in mL. A working dilution follows C1 × V1 = C2 × V2. The calculator on the site does the arithmetic.
How should the lyophilized vial be stored?
Per the product page: refrigerate at 2–8 °C, use −20 °C for long-term holding, and protect from heat, moisture and light.
How long does a prepared Selank solution stay usable?
No validated shelf life is published for research solutions. Keep it cold, label it, prepare working dilutions fresh and re-verify concentration by HPLC if the number is critical.
Where is the lot analytical data?
On the COA page where a certificate has been published. Record the lot number with each experiment.
Related reading: Selank Research Peptide: What the Evidence Shows, Selank and Semax Stack Research: Combination Design, Selank vs Semax: Readout-by-Readout Research Ledger.
References
- Vasil'eva EV, Kondrakhin EA, Salimov RM, Kovalev GI. [COMPARISON OF PHARMACOLOGICAL EFFECTS OF HEPTAPEPTIDE SELANK AFTER INTRANASAL AND INTRAPERITONEAL ADMINISTRATION TO BALB/c AND C57BL/6 MICE.]. Eksp Klin Farmakol. 2016;79(9):3-11. PMID: 29787664
- Kolomin TA, Agapova TIu, Agniullin IaV, Shram SI, Shadrina MI, Slominskiĭ PA, et al. [Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2013;63(3):365-74. PMID: 24450168
- Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-3. doi:10.1134/s0012496608040066
- Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007;337(1-2):1-24. doi:10.1016/j.ijpharm.2007.03.025
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-75. doi:10.1007/s11095-009-0045-6
- Hawe A, Wiggenhorn M, van de Weert M, Garbe JH, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913. doi:10.1002/jps.22812
- Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 1987;262(2):785-94. PMID: 3805008
- Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007;12(5):505-23. doi:10.1080/10837450701481157
- Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. doi:10.3389/fphar.2016.00031
- Ashmarin IP, Baglikova KE, Edeeva SE, Zolotarev IuA, Kozik VS, Dadaian AK, et al. [A comparative analysis of distribution of glyprolines administered by various routes]. Bioorg Khim. 2008;34(4):464-70. PMID: 18695718
